Event agenda 12:00: Registration opens 12:30: Panel starts 13:45: Panel close and networking lunch 15:00: Close Confirmed Speakers Tomislav Sokol MEPMember SANT Committee, European Parliament Hilde […]
Join our very own Healthcare Policy Senior Manager, Adrien Samson in Madrid where he will be speaking in the panel "Innovation, Funding and Access to Orphan Drugs: Challenges and Opportunities" between 12:15 and 13:00.
Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies.
Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies.
Against the backdrop of the Belgian EU Council Presidency, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations, industry and policy to […]
Over the millennia science & technology have steadily advanced, but key unsolved challenges remain, and much more is possible. The Curious – Future Insight™ Conference brings […]
Join our Director General Dr Claire Skentelbery on 2 October 2024 where she will be speaking at the Novartis & BritCham event "Enhancing Europe’s Pharma and […]
EuropaBio is pleased to partner with CPHI Milan 2024, the biggest international pharmaceutical industry event for the thirty fifth anniversary edition. This year's edition held from […]
The World Orphan Drug Congress Europe is the largest and most established orphan drug & rare disease event worldwide. Meet over 2000 attendees, hear from 250 […]
Healthy populations are essential for Europe to achieve its vision of a secure, competitive, and prosperous continent. Yet, European health systems are navigating a perfect storm: […]
EuropaBio, the European association representing Bioindustries, will host an evening reception co-hosted by MEP Stine Bosse (Vice-Chair, SANT) and MEP Eszter Lakos (Member, ITRE), to discuss […]
This joint webinar, organised in partnership between the EMA and the industry, aims to provide a platform for discussion and awareness on current and future EMA post-authorization […]
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
